Skip to main content
Premium Trial:

Request an Annual Quote

Antibody Maker MorphoSys Purchases Biogenesis for $8.6M in Cash

NEW YORK, Feb. 4 (GenomeWeb News) - MorphoSys of Munich has acquired immunological reagent provider Biogenesis of Poole, UK, and its US affiliate of the same name for approximately £4.55 million ($8.6 million) in cash, the antibody maker said last month.


MorphoSys purchased the two companies, which have 28 employees in total, for £5.25 million less net debt of £700,000. Biogenesis UKhad £1.8 million in revenues during fiscal year 2004; Biogenesis US had $1 million in revenues. Both Biogenesis companies will become wholly owned subsidiaries of MorphoSys.


MorphoSys said it hopes the acquisition will help it increase market channels for its own HuCAL antibody technology. The company also plans to support Biogenesis' existing portfolio of research products.

Following the acquisition, MorphoSys is one of the top five European suppliers of research antibodies, according to the company.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.